ripretinib


( Last Updated : September 16, 2021)
Generic Name:
ripretinib
Project Status:
Pending
Therapeutic Area:
Gastrointestinal stromal tumours
Manufacturer:
Medison Pharma Canada Inc.
Call for patient/clinician input open:
Brand Name:
Qinlock
Project Line:
Reimbursement Review
Project Number:
PC0265-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.